Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A trial to evaluate the pharmacokinetics, safety, and tolerability of MK-7655A in children less than 18 years old with confirmed or suspected gram-negative infections
To obtain plasma PK data and characterize the PK profile of imipenem, cilastatin, and relebactam (REL) following administration of a single IV dose of IMI/REL in pediatric subjects from birth to less ...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
MK-3682 + Ruzasvir for 12 weeks in Subjects with HCV GT1-6 Infection
-To evaluate the efficacy of co-administered MK-3682 (450 mg) + Ruzasvir (180 mg) as assessed by the proportion of subjects achieving sustained virologic response (SVR) at 12 weeks post-treatment (SVR...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Single Dose of MK-0517 for Prevention of CINV in Pediatric Subjects
Efficacy: To compare the single IV dose of fosaprepitant (in combination with ondansetron) to the ondansetron alone regimen with respect to the efficacy endpoint of Complete Response in the delayed ph...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
PK Study in Adolescents and Young Adults Treated with Glucocorticoids
-To assess the safety and tolerability of single doses of odanacatib in mature adolescents. -To compare plasma pharmacokinetic parameters [AUC0-∞, AUC0-168hr, Cmax, C168hr, Tmax, apparent terminal t½...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Pediatric PK Study (POS IV and PFS)
To evaluate the pharmacokinetics (PK) of POS IV solution and POS Powder for Oral Suspension (PFS) administered to immunocompromised pediatric subjects (ages 2 years to 17 years)with neutropenia or exp...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
MK-5172 in Combination with MK-8742 in Treatment-Naïve Subjects
•To evaluate the efficacy of MK-5172 in combination with MK-8742 as assessed by the proportion of subjects in the immediate treatment arm achieving SVR12 (Sustained Virologic Response 12 weeks after t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX ? 23) and Prevnar 13? (Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in Healthy Adults 50 Years of Age or Older Estudio multicéntrico y doble ciego de la seguridad, tolerabilidad e inmunogenicidad de una vacuna antineumocócica conjugada (V114) en comparación con una vacuna antineumocócica de polisacáridos (PNEUMOVAX?23) y Prevenar 13? (vacuna antineumocócica conjugada 13 valente [proteína diftérica CRM197]) en adultos sanos de 50 años o más de edad
1.-To demonstrate that the safety profile of a single dose of V114 is acceptable. 2.-To compare serotype-specific IgG geometric mean concentrations (GMCs), as measured by Merck?s pneumococcal elect...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Extension to the Odanacatib Fracture Trial (PN018)
(1) to assess long-term changes from baseline in total hip bone mineral density (BMD) after 10 years of treatment with odanacatib 50 mg once-weekly in postmenopausal osteoporotic women previously trea...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
MK-5172 in Combination with MK-8742 with and without Ribavirin (RBV) in HCV patients who failed Prior pegylated interferon (peg-IFN) and RBV treatment
1. To evaluate the efficacy of MK-5172 in combination with MK-8742 as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy),...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Merck)
Update Il y a 5 ans
MK-0431A XR in Pediatric Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformain
In pediatric subjects with inadequate control on metformin therapy, after 20 weeks: 1. To asses)s the effect of the addition of sitagliptin (MK-0431A XR) compared with the addition of placebo on A1C ...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next